Aethlon Medical, Inc.

Aethlon Medical, Inc. (OTC BB: AEMD) Healthcare

$1.00

Aethlon’s product, the Hemopurifier® filter cartridge, represents a completely novel approach to treating chronic hepatitis C (HCV), a multi-billion-dollar market in the U.S., and could potentially also be used to treat other types of viral infections, such as human immunodeficiency virus (HIV) and pandemic avian and swine influenza, bio-terror agents, and cancer. The chronic HCV population is estimated to be 3.2 million in the U.S. and 180 million worldwide.[1] The group that Aethlon is likely to target first for regulatory approval—the 15% to 48% of kidney failure patients with HCV infections[2]— represents an attractive commercial gateway because the Hemopurifier is physically compatible with kidney hemodialysis machines and HCV treatment can be administered concurrently with dialysis. Furthermore, there is an existing Medicare reimbursement code for filtration procedures that is likely to apply to the Hemopurifier, potentially creating a new source of revenue and spurring nephrologists (kidney specialists) to use the device.

Aethlon Medical creates diagnostic and therapeutic filtration devices to improve the health of individuals afflicted with infectious disease and cancer. Aethlon’s lead product, the Hemopurifier®, is a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from the human circulatory system. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV), and serves as a broadspectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier® also holds promise in cancer care, as research studies verify the Hemopurifier® effectively captures immunosuppressive exosomes that are secreted by tumors to kill-off immune cells.

At present, over sixty-five (65) Hemopurifier® treatments (representing approximately 260 hours of treatment time) have been conducted in multi-site studies at the Apollo Hospital, Fortis Hospital, and Sigma New-Life Hospital in India. The studies enrolled end-stage renal disease (ESRD) patients infected with either HCV or HIV. In addition to establishing treatment safety, robust viral load reductions have been reported in both HCV and HIV infected individuals.

Research studies have also demonstrated the Hemopurifier® is effective in capturing a broad-spectrum of viruses untreatable with drug therapy, including several of the world’s deadliest bioterror and pandemic threats. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian infl uenza (Bird Flu), the reconstructed 1918 infl uenza virus (r1918), West Nile virus (WNV), and Vaccinia and Monkeypox (MPV), which both serve as models for human smallpox infection. The studies were conducted with the assistance of researchers representing: The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID); The Centers for Disease Control and Prevention (CDC); The National Institute of Virology (NIV); The Battelle Biomedical Research Center (BBRC); and The Southwest Foundation for Biomedical Research (SFBR).

Beyond therapeutic market opportunities, Aethlon is leveraging principles underlying the Hemopurifier® technology platform to establish a pipeline of clinical and research diagnostic products and services. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.